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BACKGROUND. Previous data from an institutional pilot study in patients with
advanced or recurrent squamous cell carcinoma of the head and neck (SCCHN)
who received treated a combined chemotherapy regimen of paclitaxel, cisplatin,
and 5-fluorouracil indicated an overall response rate of 60% and a median survi-
val of 6 months. To validate these results and to determine the feasibility of this
combination, a Phase II study was conducted by the Southwest Oncology Group
(SWOG S0007).
METHODS. Patients with advanced or recurrent SCCHN were eligible if they had
received 1 previous regimen of induction/adjuvant chemotherapy or no prior
systemic therapy. Patients received treatment with paclitaxel (135 mg/m2 on Day
1), followed by cisplatin (75 mg/m2 on Day 1), and 5-fluorouracil (1000 mg/
m2per day as a 96-hour continuous infusion on Days 1–4) every 21 days.
RESULTS. Seventy-six patients received a combined total of 286 cycles of che-
motherapy. Sixty-nine patients were evaluable for response. There were 5 com-
plete responses (7%) and 23 partial responses (33%) partial responses, for an
overall response rate of 41%. The median progression-free survival was 4
months, and the median overall survival was 10 months. Six treatment-related
deaths were documented, including deaths in 2 patients who had a Zubrod PS of
2. Grade 3 or 4 neutropenia (according to National Cancer Institute Common
Toxicity Criteria [version 2.0]) was observed in 47% of patients. Other Grade 3 or
4 adverse events included mucositis (34% of patients), nausea (20% of patients),
anemia (9% of patients), and neuropathy (8% of patients).
CONCLUSIONS. The combination of paclitaxel, cisplatin, and 5-fluorouracil had
efficacy similar to that of standard treatment regimens in patients with advanced
or recurrent SCCHN but with increased toxicity. Cancer 2006;107:319–27.
 2006 American Cancer Society.
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R ecurrent squamous cell carcinoma of the headand neck (SCCHN) is fatal uniformly and
responds poorly to chemotherapy.1 The combination
of cisplatin and 5-flurouracil is considered standard
therapy,2 although newer data suggest that the com-
bination of cisplatin and paclitaxel may have equal
efficacy with less toxicity.3 Response data for the use
of single-agent paclitaxel in patients with head and
neck cancer also are well established.4 In vitro stud-
ies combining paclitaxel with cisplatin demonstrated
a synergistic interaction between these 2 agents,
whereby paclitaxel inhibited platinum-DNA adduct
repair. Studies also indicate that sequencing of these
agents, with cisplatin given after paclitaxel, is crucial
for such synergy.5
In addition to this synergistic effect, toxicity from
the combination of cisplatin and paclitaxel also has
influenced the sequencing of these 2 agents. In Phase
I trials, more pronounced neutropenia was observed
when cisplatin was given prior to paclitaxel. Pharma-
cologic data indicate that the increased toxicity prob-
ably is caused by a 25% decrease in paclitaxel
clearance when cisplatin administration precedes that
of paclitaxel. In a Phase I study of cisplatin plus pacli-
taxel, the dose-limiting toxicity was neutropenia.
Other toxicities included mild-to-moderate neurotoxi-
city, which was more prominent in patients with
heavy alcohol use or preexisting neuropathy.6
In an effort to augment the activity of 5-fluo-
rouracil and cisplatin, paclitaxel was administered
with these 2 agents in a Phase I/II pilot study at
Wayne State University.7 That study was conducted
to determine the feasibility, toxicities, and maximum
tolerated dose for the combination of paclitaxel, cis-
platin, and 5-fluorouracil in patients with recurrent,
metastatic, or locoregionally advanced SCCHN. The
overall response rate was 58%, and the 1-year survi-
val rate was 37%. The median overall survival was 6
months. Major toxicities were mucositis and neutro-
penia. Encouraged by these results, the Southwest
Oncology Group (SWOG) investigators initiated a
Phase II trial of paclitaxel, cisplatin, and 5-fluoroura-
cil in patients with advanced or recurrent SCCHN in
the cooperative group setting. The objectives of this
trial were to determine the feasibility, efficacy, and
toxicity of this triplet combination in a population
whose poor general condition often is complicated
by specific cancer morbidities.
MATERIALS AND METHODS
Eligibility
Patients with histologically proven SCCHN, which was
metastatic at diagnosis or had persisted, metastasized,
or recurred after definitive surgery or radiation ther-
apy, were eligible. Newly diagnosed patients with non-
metastatic disease were not eligible. Patients with
both measurable and nonmeasurable disease were
permitted to enter the study. Measurable disease was
defined by using the Response Evaluation Criteria in
Solid Tumors (RECIST).8 Prior chemotherapy for
recurrent or newly diagnosed metastatic disease was
not permitted. However, either 1 induction or adju-
vant chemotherapy regimen or 1 concomitant che-
moradiation regiment was permitted as long as 6
months had elapsed since the last course of che-
motherapy. Participants were required to be at least
age 18 years. When the study initially opened for
enrollment on November 1, 2000, patients were
required to have had a Zubrod performance status
(PS) 2. However, the study was closed temporarily in
August 2001 for concerns regarding patient safety.
When the study was reactivated on November 1, 2001,
enrollment was restricted to patients with a Zubrod
PS1. All patients had to have adequate renal func-
tion, as documented by a serum creatinine level 1.5
mg/dL or a creatinine clearance of 50 cc per minute.
In addition, every patient had to have an absolute
neutrophil count (ANC) 1500 mL, a platelet count
100,000 mL, a serum bilirubin level 2 times the
upper limit of normal (ULN), and alanine and aspar-
tate aminotransferase levels 1.5 times the ULN.
Patients with sensory neuropathy greater than Grade
2 were not eligible. Patients who had uncontrolled
hypertension, unstable angina, congestive heart fail-
ure, ventricular arrhythmias requiring medication, or
myocardial infarctions within 6 months of enrollment
were ineligible along with patients who had an active,
systemic malignancy within 5 years of enrollment. No
other concurrent radiation, hormone, or biologic
therapies were permitted. The study was approved by
the Institutional Review Boards at each participating
institution. All patients provided informed consent.
Treatment Plan
Patients were premedicated with dexamethasone at a
dose of 20 mg, diphenhydramine at a dose of 50 mg,
and ranitidine at a dose of 50 mg intravenously 30
minutes prior to paclitaxel administration. Paclitaxel
(135 mg/m2) was infused over 3 hours on Day 1
prior to cisplatin. Cisplatin (75 mg/m2) was given
over 30 minutes. Hydration and mannitol diuresis
were given prior to cisplatin according to the stan-
dard guidelines set forth by each institution. After
cisplatin, 5-fluorouracil (1000 mg/m2 per day) was
administered as a continuous infusion over 96 hours.
Treatment cycles were repeated at 21-day intervals if
complete recovery from toxicity occurred.
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Treatment Evaluations and Dose Modifications
Prior to enrollment, patients underwent a history
and physical examination. Pretherapy laboratory stud-
ies included a complete blood cell count with diff-
erential count and platelet count (CDP) and serum
chemistries. Renal function was monitored either by
measuring serum creatinine levels or by calculating
24-hour clearance. Computed tomography scans or
magnetic resonance images were obtained to estab-
lish baseline disease measurements prior to che-
motherapy. Chemistries and renal function were
monitored prior to each chemotherapy cycle. A CDP
was drawn on Day 15 and on Day 1 of each subse-
quent cycle. Audiograms were recommended for any
patient with hearing loss to document baseline hear-
ing status prior to cisplatin administration.
The National Cancer Institute Common Toxicity
Criteria (version 2.0) were used for the classification
of adverse events.9 Dosage modifications were based
on the nadir laboratory values of the preceding che-
motherapy cycle. Prior to August 2001, chemother-
apy was given subsequently if a patient’s ANC was
1000/mL at the time of chemotherapy administra-
tion, and dosage adjustments were made to che-
motherapy if nadir granulocyte counts were 500/
mL. Upon protocol reactivation in November 2001,
hematologic recovery to an ANC >1500/mL was
required, and dosage adjustments were made if nadir
granulocyte counts were 750 mL. Granulocyte-col-
ony stimulating factor (G-CSF) was not administered
to prevent neutropenia. Patients who experienced
Grade 3 or 4 neutropenia had G-CSF (5 mL/kg per
day) added to subsequent cycles of chemotherapy at
the discretion of their prescribing physicians. G-CSF
was given until the ANC recovered to >10,000/mL
after nadir and was discontinued 24 hours prior to
the next chemotherapy dose.
Response Criteria
Response was evaluated according to RECIST criteria.
Disease was assessed after every 2 cycles. Patients
who achieved a complete response (CR) were re-
moved from treatment after they received 3 additional
cycles of chemotherapy. Otherwise, patients were
treated until they developed disease progression.
Patients who had only nonmeasurable disease were
excluded from the response analysis.
Statistical Considerations
The main objective of this study was to assess the
survival in patients with advanced or recurrent
SCCHN when they were treated with the triplet com-
bination of paclitaxel, cisplatin, and 5-fluorouracil
discussed above. The regimen was considered
unpromising if the true median survival was 6
months and was of considerable interest if the med-
ian survival was 9 months. With 65 patients ac-
crued over 12 months and an additional 12 months
of follow-up, the power of a 1-sided level .05 expo-
nential score test was .90. If the observed median
survival was 7.5 months, then the regimen was to
be considered for further study.
Secondary objectives were to assess response in
the subset of patients who had measurable disease,
progression-free survival, and toxicity. Assuming that
55 patients had measurable disease, this number
was sufficient to estimate the probability of response
(confirmed and unconfirmed, complete and partial)
to within 613% (95% confidence interval [95% CI]).
Sixty-five patients were sufficient to estimate the
probability of any specific adverse events to within
612% (95% CI). Any adverse event that occurred
with at least 5% probability was likely to have been
seen once (96% chance). In addition, 65 patients
were sufficient to estimate progression-free survival
at any selected time points, namely, 1 year to 2
years, to within 612% (95% CI). Median overall sur-
vival and median progression-free survival were
derived from estimates that were obtained by using
the method of Kaplan and Meier.10
RESULTS
Patient Characteristics
From November 1, 2000 to May 15, 2003, 78 patients
were registered from 34 participating institutions.
Two patients were ineligible because they had insuf-
ficient documentation. On August 14, 2001, the study
was closed temporarily because of concerns regard-
ing patient safety. The protocol was revised to allow
for better tolerance of treatment, which included
changing the requirements for chemotherapy dosing
based on granulocyte recovery and changing the
Zubrod PS eligibility from 2 to 1.
Of the 76 eligible patients, 69 patients (91%) had
measurable disease, and 7 patients (9%) had only
nonmeasurable disease. Response was not determin-
able in 11 patients who had measurable disease
because of inadequate assessment (10 patients) or
early death (1 patient). Patient characteristics are
noted in Table 1.
Toxicity
All 76 eligible patients were evaluated for adverse
events. Thirty-two patients (42%) were hospitalized
during the course of this study for a total of 40 hos-
pitalizations. Two patients were admitted on 3 differ-
ent occasions, and 5 patients were hospitalized
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twice. The primary reason for hospitalization was
dehydration related to Grade 3 or 4 mucositis/eso-
phagitis, followed by febrile neutropenia with or
without infection.
Six treatment-related deaths occurred and are
reported in Table 2. Common adverse events are
recorded in Table 3. Thirty-three patients (43%)
experienced a Grade 3 adverse event, and 28 patients
(37%) experienced a Grade 4 adverse event. The most
commonly reported Grade 3 or worse toxicity was
neutropenia. Eleven patients (14%) developed Grade 3
or worse infection with neutropenia. Twenty patients
(26%) were given G-CSF with all subsequent cycles of
chemotherapy. Six patients (8%) required transfusions
of packed red blood cells, and 13 patients (17%) were
treated with erythropoietin. Grade 4 thrombocytope-
nia was observed in 2 patients, both of whom were
given platelet transfusions.
Of the 5 patients who received >6 cycles of che-
motherapy, 3 patients died from infection during
their last cycle of treatment. All 5 of those patients
developed Grade 3 or 4 asthenia, 2 experienced
Grade 4 motor neuropathy, and 3 developed Grade 2
motor and sensory neuropathies.
Treatment and Tolerance
In total, 286 cycles of chemotherapy were adminis-
tered to 76 eligible patients during the course of this
study. There were 132 full-dose cycles (46%) and 154
reduced-dose cycles (54%). The median number of
chemotherapy cycles delivered was 4 (range, 1–10
cycles). Thirteen patients (17%) received only 1 cycle
of chemotherapy, 58 patients (76%) received between
2 and 6 cycles of chemotherapy, and 5 patients (7%)
received >6 cycles of chemotherapy. Of the patients
who received >6 cycles, 2 patients had a CR, and 3
patients had stable disease with palliation of pain
from larger tumor burdens. Dosage reductions that
were required during chemotherapy administration
and adverse events that prompted dosage reductions
are summarized in Table 4.
Response to Treatment
Of the 69 patients who were evaluable for response,
5 patients (7%) attained CRs, 2 of which were uncon-
firmed according to the RECIST criteria. Twenty-
three patients (33%) had partial responses, including
14 confirmed and 9 unconfirmed responses. The
overall response rate was 41% (95% CI, 29-53%).
Progression-free survival and overall survival are
illustrated in Figure 1 and Figure 2, respectively. The
median survival was 10 months (95% CI, 7–12
months). The estimate 1-year survival rate was 42%
(95% CI, 31–53%). The median progression-free sur-
vival was 4 months (95% CI, 3–5 months). The med-
ian time to follow-up for patients who remained
alive was 25 months.
DISCUSSION
Historically, the median survival for patients with
advanced/recurrent SCCHN who received palliative
chemotherapy has been 6 months.1,2 SWOG 0007
was designed to show an improvement in overall
survival, and our results demonstrated a positive
outcome with a median survival of 10 months.
Seventy-six patients were enrolled on this study; and,
to our knowledge, it is the largest reported, nonran-
domized Phase II experience in patients with meta-



















Surgery only 2 3
RT only 4 5
Surgery plus RT 57 72
Chemotherapy plus
(RT with or without surgery)
10 12
None or unknown 3 8
Sites of disease at baseline
Locoregional only 25 32











Sepsis with ANC unknown 2 2 and 2
Sepsis with neutropenia 2 0 and 1
Other
Inanition 1 1
Pulmonary edema 1 1
PS indicates performance status; ANC, absolute neutrophil count.
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Table 5 summarizes data from several random-
ized and nonrandomized trials among patients
with advanced/recurrent SCCHN. The median survi-
val of 10 months observed in the current study sur-
passed our predetermined cut-off level of interest
and was comparable to the survival observed with
other platinum-based and paclitaxel-based regi-
mens3,11–14 and with single-agent paclitaxel adminis-
tered at a dose of 250 mg/m2 over 24 hours.4
Objective response rates in the current study also
were similar to other studies that used triplet combi-
nations.14–16 SWOG 0007, however, enrolled more pa-
tients with distant metastatic disease (67%) com-
pared with other nonrandomized trials. Thus, our
results are encouraging, because published data indi-
cate that chemotherapy may be more effective in
patients with locoregional recurrence than in pa-




No. of patients (%)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Anemia 32 (42) 28 (37) 6 (8) 1 (1) 0
Thrombocytopenia 17 (22) 2 (3) 0 2 (3) 0
Leucopenia 14 (18) 14 (18) 23 (30) 8 (11) 0
Neutropenia 10 (13) 11 (14) 20 (26) 16 (21) 0
Febrile neutropenia 0 0 2 (3) 0 0
Infection with neutropenia 0 0 6 (8) 1 (1) 1 (1)
Respiratory infection with neutropenia 0 0 2 (3) 0 1 (1)
Esophagitis/dysphagia 10 (13) 12 (16) 10 (13) 5 (7) 0
Mucositis/stomatitis 8 (11) 24 (32) 19 (25) 7 (9) 0
Diarrhea 14 (18) 9 (12) 4 (5) 2 (3) 0
Nausea 15 (20) 22 (29) 15 (20) 0 0
Sensory neuropathy 14 (18) 3 (4) 3 (4) 0 0
Motor neuropathy 4 (5) 3 (4) 1 (1) 2 (3) 0
Asthenia 18 (24) 28 (37) 13 (17) 2 (3) 0
Renal/creatinine 8 (10) 7 (9) 1 (1) 0 0
TABLE 4
Dosage Reductions for Subsequent Cycles of Chemotherapy
Drug dosages reduced
Total No.
of patients Adverse event No.*
No. of patients who
required omission of
drug from regimen
Paclitaxel/5-FU/cisplatin 27 Grade 3/4 neutropenia 27
Grade 2/4 mucositis 9
Grade 3/4 esophagitis 5
Grade 3 nausea 15 0
Grade 2 renal/creatinine 4
Grade 4 thrombocytopenia 2
Grade 3/4 motor neuropathy 3
Paclitaxel/cisplatin 2 Grade 3 diarrhea 2
Grade 3 neutropenia 2 0
5-FU only 17 Grade 3/4 mucositis 17
Grade 3/4 diarrhea 4 3
Grade 3/4 esophagitis 10
Paclitaxel/cisplatin 3 Grade 3 sensory neuropathy 3 0
Cisplatin only 2 Grade 2/3 renal/creatinine 2 2
5-FU indicates 5-fluorouracil.
* The number of patients who experienced a particular adverse event that led to dosage reductions for 1 drugs. Patients who required reductions of only 1 or 2
drug dosages either had 1 drug eliminated from the treatment regimen prior to (i.e., cisplatin in the case of paclitaxel/5-FU or 5-FU in the case of paclitaxel/cis-
platin) or required dosage reductions specific only to 1 drug (i.e., cisplatin and renal toxicity).
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The use of induction chemotherapy is becoming
more favorable for the treatment of patients with
SCCHN, with published trials demonstrating a survi-
val benefit from regimens of combined cisplatin and
5-fluorouracil.19–21 Newer data show an improve-
ment in survival when taxanes are added to cisplatin
and 5-fluorouracil in the neoadjuvant setting. This
improvement in survival may be caused by the phar-
macologic effect of the taxanes or by specific prog-
nostic factors.22 Hitt et al.23 demonstrated an im-
provement in CR rate, time to treatment failure, and
overall survival when paclitaxel was added to cispla-
tin and 5-flurouracil compared with cisplatin and 5-
fluorouracil. Similarly, the European Organization for
Research and Treatment of Cancer randomized
patients with nonresectable, locally advanced
SCCHN to receive cisplatin and 5-fluorouracil versus
cisplatin, 5-fluorouracil, and docetaxel as neoadju-
vant chemotherapy prior to definitive radiation ther-
apy.24 The triplet study arm had statistically sig-
nificant improvements in response rate, progression-
free survival, and overall survival with fewer toxic
deaths.
Unlike SWOG 0007, the studies described above
treated a different patient population (i.e., patients
who previously had not received chemotherapy or
radiation therapy, patients with a PS of 0 or 1). In
general, patients with recurrent SCCHN who receive
combination chemotherapy and who have a PS 1
have more favorable outcomes,25 including patients
with a PS 1 who are older than 70 years.26 Nearly
75% of the patients enrolled in our current study
had a PS 1. Five patients with a PS of 2 either died
or suffered Grade 4 adverse events, prompting revi-
sion of the study to include only patients with a PS
1. Despite this change, 4 additional treatment-
related deaths occurred, suggesting that triplet com-
binations that use taxanes, cisplatin, and 5-fluorour-
acil should be administered to only the healthiest
patients.
Toxicity was also a major problem. Seventeen
percent of the eligible patients received only 1 cycle
of chemotherapy, and almost 75% of patients
required dosage reductions with subsequent cycles
of chemotherapy. In addition, nearly 50% of patients
were hospitalized on 1 or more occasion. Although
the study was revised with more stringent guidelines
for chemotherapy administration with respect to
hematologic parameters, the overwhelming number
of hospitalizations and dosage reductions related to
mucositis, esophagitis, and neutropenia indicate that
the dosages of 5-fluorouracil, cisplatin, and paclitaxel
in our study were too high for this comprised popu-
lation, which included a large number of patients
with metastatic disease. Of all agents, 5-fluorouracil
demanded the most dosage reductions, with >60%
of patients requiring 1 or more dosage adjustments.
Because progression-free survival was shortened by
so many toxic events, we know now that the 5-fluo-
rouracil dose should have been much lower than
what was prescribed in our study. Hitt et al.27
reported that the recommended dose of 5-fluoroura-
cil in the combination of paclitaxel, cisplatin, and 5-
fluorouracil as induction chemotherapy is 500 mg/
m2. This dosage did not have a negative impact on
response and allowed for significantly less toxicity.
The rate of Grade 3 and 4 neutropenia reported
in our study was 47%. This degree of neutropenia
may be not only dose-related but also schedule-
dependent. In the current study, both paclitaxel and
cisplatin were administered on Day 1 followed by a
96-hour continuous infusion of 5-fluorouracil. Re-
sults from a dose-finding study that was conducted
in Italy showed that paclitaxel at a dose of 160 mg/
m2 on Day 1, cisplatin at a dose of 25 mg/m2 on
Days 1 through 3, and 5-fluorouracil at a dose of
250 mg/m2 on Days 1 through 3 can be adminis-
tered safely without growth factor support.15 It is
possible that high-dose cisplatin inhibits the clear-
ance of paclitaxel even if paclitaxel is administered
FIGURE 1. Progression-free survival is illustrated by treatment arm. 5FU
indicates 5-fluorouracil; CDDP, cisplatin.
FIGURE 2. Overall survival is illustrated by treatment arm. 5FU indicates
5-fluorouracil; CDDP, cisplatin.
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prior to cisplatin. High-dose cisplatin administered
1 day after paclitaxel also is associated with lower
rates of Grade 4 neutropenia.27 Thirty percent of
the patients on SWOG 0007 who were treated with 2
or more cycles of chemotherapy required support
with G-CSF. Staar et al.28 reported a reduction in
locoregional control when G-CSF was administered
prophylactically to patients who were receiving che-
moradiation for locally advanced SCCHN. Whether
this had any impact in terms of disease control in
our study is not known, because our patients did
not receive concomitant radiation therapy.
Neurotoxicity also was a problem in patients
who received 6 cycles of chemotherapy. Moreover,
patients who received 450 mg/m2 of cisplatin
required dosage reductions for either sensory or
motor neuropathies. Because paclitaxel also is asso-
ciated with neurotoxicity, it would have been reason-
able to substitute carboplatin for cisplatin once
patients had received a cumulative cisplatin dose of
400 mg/m2 in an effort to reduce neurotoxic effects.
Such data have been reported in patients with ovar-
ian cancer who received prolonged courses of pla-
tinum and paclitaxel.29,30 Similarly, an editorial in
The Journal of Clinical Oncology by Takimoto and
Rowinksy sited several studies in various solid tumor
types that demonstrated improvements in response
rates when the dose intensity of paclitaxel was in-
creased; however, toxicity also was enhanced, and
improvements in overall survival were negligible.31
In conclusion, the combination of paclitaxel, cis-
platin, and 5-fluorouracil had similar efficacy but
increased toxicity compared with standard treatment
regimens in patients with advanced or recurrent
SCCHN. Given the significant hematologic and non-
hematologic toxicities, this regimen may not be
appropriate for all patients in the palliative setting.
In the alternative, this combination may prove to be
useful as neoadjuvant therapy, as demonstrated by
the high number of responders in our study who
had widespread disease.
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